| Literature DB >> 31044070 |
Jiewei Cui1, Zhixin Liang1, Zhenfei Mo1, Jianpeng Zhang2.
Abstract
Objective: Coagulase-negative staphylococci (CoNS) are one of the major opportunistic pathogens and the incidence of CoNS bacteraemia is increasing. However, most of the CoNS-positive blood cultures are contaminants rather than true CoNS bacteraemia. In order to minimize contamination, we defined true CoNS bacteraemia as the patient that has two or more identical CoNS-positive blood cultures drawn within 48 h in this study and the objective of this study was to analyse the species distribution and antibiotic resistance and to identify risk factors for 30-day mortality of the true CoNS-bacteraemia. Method: By reviewing the electronic medical database, this study retrospectively analysed patients diagnosed as CoNS bacteraemia by blood cultures in a comprehensive tertiary care hospital in China from January 1, 2014, to December 31, 2017. Result: A total of 1241 patients with 1562 episodes of CoNS-positive blood cultures were recorded in the database but only 157 patients were finally diagnosed as true CoNS bacteraemia after contaminants were excluded. All these 157 patients (12.7%, 157/1241) had bacteraemia-related clinical symptoms. Among the 157 patients, the most common species were Staphylococcus hominis (40.8%), Staphylococcus epidermidis (36.3%) and Staphylococcus capitis (11.5%). The antimicrobial susceptibility tests showed that all CoNS had a high rate of resistance to penicillin (94.9%), oxacillin (93.6%) and erythromycin (92.4%). Resistance to gentamicin (22.3%) and rifampicin (10.8%) was low, and none of the bacteria were resistant to vancomycin or linezolid. The 30-day mortality of patients with CoNS bacteraemia was up to 12.7% (20/157), and the multivariate logistics regression analysis showed that chronic renal failure (OR 5.9, 95% CI 1.6-21.5, p = 0.007) and chronic liver failure (OR 4.0, 95% CI 1.2-13.1, p = 0.024) were both the significant independent risk factors for the 30-day mortality of CoNS bacteraemia.Entities:
Keywords: Antimicrobial resistance; Bacteraemia; Coagulase-negative staphylococci; Risk factors; Species distribution
Mesh:
Substances:
Year: 2019 PMID: 31044070 PMCID: PMC6480775 DOI: 10.1186/s13756-019-0523-5
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Fig. 1Details on patient enrolment in this study
The distribution of species and their antimicrobial susceptibility in CoNS bacteraemia
| Species | No of isolates | Rate of resistance to a panel of 12 antibiotics (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEN | OXA | ERY | CEF | CLN | LEV | MOX | SUL | GEN | RIF | VAN | LIN | ||
| Total | 157 (100%) | 94.9 | 93.6 | 92.4 | 78.3 | 73.2 | 72.6 | 71.3 | 59.9 | 22.3 | 10.8 | 0 | 0 |
|
| 64 (40.8%) | 96.9 | 92.2 | 98.4 | 84.4 | 85.9 | 79.7 | 79.7 | 62.5 | 9.4 | 9.4 | 0 | 0 |
|
| 57 (36.3%) | 96.5 | 96.5 | 87.7 | 75.4 | 61.4 | 61.4 | 59.6 | 71.9 | 28.1 | 15.7 | 0 | 0 |
|
| 18 (11.5%) | 77.8 | 83.3 | 88.9 | 61.1 | 77.8 | 72.2 | 66.7 | 11.1 | 16.7 | 0 | 0 | 0 |
|
| 12 (7.6%) | 100 | 100 | 91.7 | 91.7 | 50 | 100 | 100 | 66.7 | 75 | 16.7 | 0 | 0 |
|
| 3 | 3 | 3 | 3 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
|
| 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 |
|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
S. Staphylococcus, PEN penicillin, OXA oxacillin, ERY erythromycin, CEF cefoxitin, CLN clindamycin, LEV levofloxacin, MOX moxifloxacin, SUL trimethoprim/sulfamethoxazole, GEN gentamicin, RIF rifampicin, VAN vancomycin and LIN linezolid
aThe data were described as “n” since each frequency was too small
Clinical Characteristics and univariate logistics analysis of risk factors for 30-day mortality of patients diagnosed with CoNS bacteraemia
| Total | Survival | Non-survival | OR | 95% CI | ||
|---|---|---|---|---|---|---|
| Age | 64.0 (48.0–80.0) | 62.0 (48.0–80.0) | 72.0 (62.8–80.2) | 1.0 | 1.0–1.0 | 0.112 |
| ≥60 years | 92 (58.6%) | 76 (55.5%) | 16 (80.0%) | 3.2 | 1.0–10.1 |
|
| < 60 years | 65 (41.4%) | 61 (44.5%) | 4 (20.0%) | |||
| Gender | ||||||
| female | 49 (31.2%) | 42 (30.7%) | 7 (35%) | 1.2 | 0.5–3.3 | 0.696 |
| male | 108 (68.8%) | 95 (69.3%) | 13 (65.0%) | |||
| Residence in ICU | 66 (42.0%) | 52 (38.0%) | 14 (70.0%) | 3.8 | 1.4–10.5 |
|
| APACHE II score | 12.0 (6.0–20.0) | 11.0 (1.0–36.0) | 20.0 (6.0–32.0) | 1.1 | 1.0–1.2 |
|
| qSOFA score | ||||||
| 2 and 3 | 36 (22.9%) | 26 (19.0%) | 10 (50.0%) | 4.3 | 1.6–11.3 |
|
| 0 and 1 | 121 (77.1%) | 111 (81.0%) | 10 (50.0%) | |||
| Prior hospital stay length | 15.0 (4.0–35.0) | 13.0 (4.0–31.0) | 30.5 (5.8–46.2) | 2.8 | 1.0–1.0 | 0.707 |
| ≥28 days | 53 (33.8%) | 42 (31%) | 11 (55%) | 2.8 | 1.1–7.2 |
|
| < 28 days | 104 (66.2%) | 95 (69.3%) | 9 (45.0%) | |||
| Comorbidities | ||||||
| Cardiovascular disease | 95 (60.5%) | 82 (59.9%) | 13 (65.0%) | 1.2 | 0.5–3.3 | 0.661 |
| Pneumonia | 73 (46.5%) | 59 (43.1%) | 14 (70.0%) | 3.1 | 1.1–8.5 |
|
| Cerebrovascular disease | 46 (29.3%) | 42 (30.7%) | 4 (20.0%) | 0.6 | 0.2–1.8 | 0.333 |
| Diabetes mellitus | 36 (22.9%) | 32 (23.4%) | 4 (20.0%) | 0.8 | 0.3–2.6 | 0.739 |
| Chronic liver failure | 29 (18.5%) | 20 (14.6%) | 9 (45.0%) | 4.8 | 1.8–13.0 |
|
| Chronic renal failure | 27 (17.2%) | 18 (13.1%) | 9 (45.0%) | 5.4 | 2.0–14.9 |
|
| Solid tumor | 28 (17.8%) | 24 (17.5%) | 4 (20.0%) | 1.2 | 0.4–3.8 | 0.787 |
| Hematologic malignancy | 11 (7.0%) | 9 (6.6%) | 2 (10.0%) | 1.6 | 0.3–7.9 | 0.577 |
| Neutropenia | 12 (7.6%) | 11 (8.0%) | 1 (5.0%) | 0.6 | 0.1–4.9 | 0.637 |
| Prior treatments | ||||||
| Indwelling CVC | 88 (56.1%) | 74 (54.0%) | 14 (70.0%) | 2.0 | 0.7–5.5 | 0.184 |
| Indwelling urinary catheter | 67 (42.7%) | 57 (41.6%) | 10 (50.0%) | 1.4 | 0.5–3.6 | 0.480 |
| Invasive MV | 38 (24.2%) | 33 (24.1%) | 5 (25.0%) | 1.1 | 0.4–3.1 | 0.929 |
| Broad-spectrum antibiotics | 31 (19.7%) | 45 (32.8%) | 6 (30.0%) | 0.9 | 0.3–2.4 | 0.800 |
| Surgery | 28 (17.8%) | 26 (19.0%) | 2 (10.0%) | 0.5 | 0.1–2.2 | 0.337 |
| Renal replacement therapy | 9 (5.7%) | 7 (5.1%) | 2 (10.0%) | 2.1 | 0.4–10.7 | 0.389 |
| Chemotherapy | 4 (2.5%) | 3 (2.2%) | 1 (5.0%) | 2.4 | 0.2–23.8 | 0.469 |
| Laboratory test results | ||||||
| CRP (mg/dL) | 3.9 (2.3–8.6) | 3.9 (0.1–29.4) | 3.9 (1.2–78.2) | 1.0 | 1.0–1.1 | 0.175 |
| Leukocyte (×109/L) | 8.2 (5.2–11.9) | 8.2 (4.7–12.1) | 8.3 (6.2–11.1) | 1.0 | 0.9–1.1 | 0.706 |
| Neutrophils (×109/L) | 6.5 (3.6–9.5) | 6.6 (3.3–9.9) | 6.3 (4.1–9.1) | 1.0 | 0.9–1.1 | 0.643 |
| ALT (U/L) | 24.6 (13.5–41.9) | 24.4 (3.7–147.0) | 30.2 (1.7–419.1) | 1.0 | 1.0–1.0 |
|
| SCr (μmol/L) | 63.5 (51.3–83.6) | 62.1 (22.4–1392.0) | 69.0 (37.9–791.0) | 1.0 | 1.0–1.0 | 0.690 |
| Appropriate empirical antibiotic therapy | 132 (84.1%) | 117 (85.4%) | 15 (75.0%) | 0.5 | 0.2–1.6 | 0.242 |
| Vancomycin | 40 (25.5%) | 39 (28.5%) | 1 (5.0%) | 0.1 | 0.0–1.0 | 0.052 |
| Carbapenems | 33 (21.0%) | 27 (19.7%) | 6 (30.0%) | 1.7 | 0.6–5.0 | 0.296 |
| Linezolid | 4 (2.5%) | 4 | 0 | – | – | – |
OR odds ratio, 95% CI confidence interval, CVC central venous catheter, MV mechanical ventilation, CRP c-reactive protein, ALT alanine aminotransferase, SCr serum creatinine, APACHE II acute physiology and chronic health evaluation (ii), qSOFA quick sepsis related organ failure assessment
*Bold font means that the risk factor was statistically p < 0.05 in the univariate logistics analysis and was included in the multivariate logistics analysis
The correlation coefficient between factors planed to be included in the multivariate regression analysis model
| Correlation coefficient (r) | APACHE II score | ALT | Age ≥ 60 years | Residence in ICU | qSOFA (2 and 3) | Prior hospital stay length (≥28 days) | Pneumonia | Chronic liver failure | Chronic renal failure |
|---|---|---|---|---|---|---|---|---|---|
| Appropriate empirical antibiotic therapy | −0.030 | 0.131 | 0.094 | −0.017 | 0.072 | −0.057 | −0.153 | 0.028 | −0.032 |
| Chronic renal failure |
| −0.007 | 0.006 | 0.125 | 0.073 | −0.111 | 0.049 |
| 1.000 |
| Chronic liver failure |
|
| 0.000 | 0.127 | 0.131 | 0.007 | 0.116 | 1.000 | / |
| Pneumonia |
| 0.055 |
|
|
|
| 1.000 | / | / |
| Prior hospital stay length (≥28 days) |
| −0.109 |
|
|
| 1.000 | / | / | / |
| qSOFA score (2 and 3) |
| 0.033 | 0.120 |
| 1.000 | / | / | / | / |
| Residence in ICU |
| 0.067 | 0.061 | 1.000 | / | / | / | / | / |
| Age (≥60 years) |
| −0.107 | 1.000 | / | / | / | / | / | / |
| ALT (U/L) | 0.033 | 1.000 | / | / | / | / | / | / | / |
ALT alanine aminotransferase
*Bold font means that correlation coefficient (r) was statistically p < 0.05 and there was a significant correlation between the two variables
The multivariate regression analysis of risk factors for 30-day mortality of patients diagnosed as CoNS bacteraemia
| Logistics regressiona | Cox regression | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI | HR | 95% CI | |||
| Age | ||||||
| ≥ 60 years | 3.3 | 0.9–12.6 | 0.084 | 2.6 | 0.8–8.4 | 0.100 |
| < 60 years | ||||||
| Residence in ICU | 1.7 | 0.5–5.6 | 0.399 | 1.6 | 0.6–4.8 | 0.371 |
| qSOFA score | ||||||
| 2 and 3 | 2.8 | 0.9–9.4 | 0.089 | 2.1 | 0.8–5.6 | 0.143 |
| 0 and 1 | ||||||
| Prior hospital stay length | ||||||
| ≥ 28 days | 2.6 | 0.8–9.0 | 0.132 | 1.9 | 0.7–5.2 | 0.184 |
| < 28 days | ||||||
| Pneumonia | 1.2 | 0.4–4.1 | 0.756 | 1.2 | 0.4–3.5 | 0.687 |
| Chronic liver failure | 4.0 | 1.2–13.1 |
| 2.9 | 1.1–7.6 |
|
| Chronic renal failure | 5.9 | 1.6–21.5 |
| 3.9 | 1.5–10.5 |
|
| Appropriate empirical antibiotic therapy | 0.3 | 0.1–1.1 | 0.066 | 0.3 | 0.1–1.0 | 0.060 |
aThe predicted values of the final model was 91.7%. OR odds ratio, HR hazard ratio, CI confidence interval
*Bold font means that the risk factor was statistically p < 0.05 and was the independent risk factor among the 8 factors